PHARMASOLE 30 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

pharmasole 30 mg tabletti, kalvopäällysteinen

betapharm arzneimittel gmbh - mirtazapinum - tabletti, kalvopäällysteinen - 30 mg - mirtatsapiini

PHARMASOLE 45 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

pharmasole 45 mg tabletti, kalvopäällysteinen

betapharm arzneimittel gmbh - mirtazapinum - tabletti, kalvopäällysteinen - 45 mg - mirtatsapiini

Cleari 0.12 mg/ml silmätipat, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

cleari 0.12 mg/ml silmätipat, liuos

elara pharmaservices europe limited - naphazoline hydrochloride - silmätipat, liuos - 0.12 mg/ml - nafatsoliini

KEFAVET VET 50 mg/ml rakeet oraalisuspensiota varten Suomi - suomi - Fimea (Suomen lääkevirasto)

kefavet vet 50 mg/ml rakeet oraalisuspensiota varten

orion corporation - cefalexinum monohydricum - rakeet oraalisuspensiota varten - 50 mg/ml - kefaleksiini

Rosuvastatin Xiromed 5 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

rosuvastatin xiromed 5 mg tabletti, kalvopäällysteinen

medical valley invest ab - rosuvastatin calcium - tabletti, kalvopäällysteinen - 5 mg - rosuvastatiini

Rosuvastatin Xiromed 10 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

rosuvastatin xiromed 10 mg tabletti, kalvopäällysteinen

medical valley invest ab - rosuvastatin calcium - tabletti, kalvopäällysteinen - 10 mg - rosuvastatiini

Rosuvastatin Xiromed 20 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

rosuvastatin xiromed 20 mg tabletti, kalvopäällysteinen

medical valley invest ab - rosuvastatin calcium - tabletti, kalvopäällysteinen - 20 mg - rosuvastatiini

Rosuvastatin Xiromed 40 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

rosuvastatin xiromed 40 mg tabletti, kalvopäällysteinen

medical valley invest ab - rosuvastatin calcium - tabletti, kalvopäällysteinen - 40 mg - rosuvastatiini

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Euroopan unioni - suomi - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogreelin hydrokloridi - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboottiset aineet - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Skytrofa (previously Lonapegsomatropin Ascendis Pharma) Euroopan unioni - suomi - EMA (European Medicines Agency)

skytrofa (previously lonapegsomatropin ascendis pharma)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - aivolisäkkeen ja hypotalamuksen hormonit ja analogit - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.